Patents by Inventor Ofer Levy

Ofer Levy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200369769
    Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
    Type: Application
    Filed: November 28, 2018
    Publication date: November 26, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Compugen LTD.
    Inventors: Lars RÖSE, Uwe GRITZAN, Julia HÜTTER, Spencer LIANG, Andrew POW, John HUNTER, Ofer LEVY, Ilan VAKNIN
  • Patent number: 10795684
    Abstract: A processor includes a front end including circuitry to decode an instruction from an instruction stream and a core including circuitry to process the instruction. The core includes an execution pipeline, a dynamic core frequency logic unit, and a counter compensation logic unit. The execution pipeline includes circuitry to execute the instruction. The dynamic core frequency logic unit includes circuitry to squash a clock of the core to reduce a core frequency. The clock may not be visible to software. The counter compensation logic unit includes circuitry to adjust a performance counter increment associated with a performance counter based on at least the dynamic core frequency logic unit circuitry to squash a clock of the core to reduce a core frequency.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: October 6, 2020
    Assignee: Intel Corporation
    Inventors: Ahmad Yasin, Eti Pardo-Fridman, Ofer Levy
  • Publication number: 20200282048
    Abstract: Provided herein are imidazopyrimidine compounds for use in enhancing human immune response and/or as adjuvants in vaccines.
    Type: Application
    Filed: November 14, 2018
    Publication date: September 10, 2020
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Ofer Levy, David J. Dowling, Francesco Borriello, David A. Scott, Spencer E. Brightman, Frederic Feru
  • Publication number: 20200270343
    Abstract: A monoclonal or polyclonal antibody or an antigen binding fragment thereof comprising an antigen binding site that binds specifically to an isolated polypeptide comprising amino acids of the soluble ectodomain of a sequence selected from the group consisting of SEQ ID NOs:3 and 5, or a fragment, thereof, or an epitope thereof; for use in treatment of cancer, wherein immune cells in the microenvironment of said cancer express said isolated polypeptide.
    Type: Application
    Filed: June 8, 2018
    Publication date: August 27, 2020
    Inventors: Ofer LEVY, Gad S. COJOCARU, Liat DASSA, Tal FRIDMAN-KFIR, Ilan VAKNIN, Einav GANGULI, Finav GANGULI, Drew PARDOLL
  • Publication number: 20200261400
    Abstract: A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying to the skin of a subject in need of said treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of up to about 40 weeks to about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75% to about 85%.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 20, 2020
    Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
  • Publication number: 20200261395
    Abstract: A regimen for the therapeutic treatment of rosacea, which includes topically applying to the skin of a subject a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in the pharmaceutical composition. The pharmaceutical composition is applied once daily for a period of about 2 weeks, about 4 weeks, about 8 weeks and about 12 weeks. The treatment regimen achieves a success rate of at least about 6%, wherein the success rate is defined as a percentage increase in the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition. The treatment regimen may also achieve significantly greater reduction in inflammatory lesion counts compared to treatment with vehicle alone.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 20, 2020
    Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
  • Publication number: 20200261397
    Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 20, 2020
    Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
  • Publication number: 20200261399
    Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 20, 2020
    Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
  • Publication number: 20200261402
    Abstract: A regimen for the therapeutic treatment of moderate to severe erythema symptoms in rosacea patients, the regimen comprising topically applying to the skin of a subject in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 12 weeks, to achieve a percentage decrease of about 60% in a population exhibiting moderate to severe erythema symptoms when measured at about 12 weeks after initial treatment of the population with the pharmaceutical composition.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 20, 2020
    Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
  • Publication number: 20200261401
    Abstract: A regimen is described for the therapeutic treatment of rosacea including topically applying to the skin of a subject in need of the treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of at least about 2 weeks, about 4 weeks, about 8 weeks or about 12 weeks. A decrease in Patient Assessment of Papulopustular Rosacea Signs and Symptoms (PAPSS) is at least about 40% after treatment with the pharmaceutical composition for about 4 weeks, and a decrease in Patient Assessment of Papulopustular Rosacea Impacts (PAPI) is from about 60% to about 70% after treatment with the pharmaceutical composition for at least about 8 weeks.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 20, 2020
    Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
  • Publication number: 20200256760
    Abstract: Some demonstrative embodiments include apparatuses, systems and/or methods of determining one or more optical parameters of a lens of eyeglasses. For example, a product may include one or more tangible computer-readable non-transitory storage media including computer-executable instructions operable to, when executed by at least one computer processor, enable the at least one computer processor to process at least one captured image of at least one reflection of a flash on a lens of eyeglasses; and determine one or more optical parameters of the lens based at least on the at least one captured image.
    Type: Application
    Filed: January 27, 2020
    Publication date: August 13, 2020
    Applicant: 6 OVER 6 VISION LTD.
    Inventors: Ofer Limon, Shahar Levy, Alexander Zlotnik, Maya Aviv
  • Patent number: 10736753
    Abstract: A delivery device includes a guide tool and an impact tool. The guide tool includes an elongate body formed with a longitudinal guide channel, whose inner perimeter is made to complement an outer contour of an implant. The elongate body is formed with a longitudinal impact-tool channel, whose inner perimeter is made to complement an outer contour of the impact tool.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: August 11, 2020
    Assignee: ZYGOFIX LTD.
    Inventors: Uri Arnin, Ofer Levy
  • Patent number: 10731129
    Abstract: Artificial tissue constructs (TCs), methods of making the TCs, uses thereof, and kits comprising the TCs are provided. TCs are useful for vaccine evaluation for human adult, human non-newborn, and newborns.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: August 4, 2020
    Assignee: Children's Medical Center Corporation
    Inventors: Guzman Sanchez-Schmitz, Ofer Levy, Chad Stevens
  • Publication number: 20200225113
    Abstract: Some demonstrative embodiments include apparatuses, systems and/or methods of determining one or more optical parameters of a lens of eyeglasses. For example, a product may include one or more tangible computer-readable non-transitory storage media including computer-executable instructions operable to, when executed by at least one computer processor, enable the at least one computer processor to process at least one captured image of at least one reflection of a flash on a lens of eyeglasses; and determine one or more optical parameters of the lens based at least on the at least one captured image.
    Type: Application
    Filed: January 27, 2020
    Publication date: July 16, 2020
    Applicant: 6 OVER 6 VISION LTD.
    Inventors: Ofer Limon, Shahar Levy, Alexander Zlotnik, Maya Aviv
  • Patent number: 10712233
    Abstract: Some demonstrative embodiments include apparatuses, systems and/or methods of determining one or more optical parameters of a lens of eyeglasses. For example, a product may include one or more tangible computer-readable non-transitory storage media including computer-executable instructions operable to, when executed by at least one computer processor, enable the at least one computer processor to implement operations of determining one or more optical parameters of a lens of eyeglasses. The operations may include processing at least one image of an object captured via the lens; and determining the one or more optical parameters of the lens based on the at least one image.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: July 14, 2020
    Assignee: 6 OVER 6 VISION LTD.
    Inventors: Ofer Limon, Haim Bachar, Nir Altmark, Shahar Levy
  • Publication number: 20200210178
    Abstract: A processor includes a counter to store a cycle count that tracks a number of cycles between retirement of a first branch instruction and retirement of a second branch instruction during execution of a set of instructions. The processor further includes a stack of registers coupled to the counter, wherein the stack of registers is to store branch type information including: a first value of the counter when the first branch instruction is retired; a second value of the counter when the second branch instruction is retired; a first type information value indicating a type of the first branch instruction; and a second type information value indicating a type of the second branch instruction.
    Type: Application
    Filed: March 6, 2020
    Publication date: July 2, 2020
    Inventors: Michael W. Chynoweth, Jonathan D. Combs, Joseph K. Olivas, Beeman C. Strong, Rajshree A. Chabukswar, Ahmad Yasin, Jason W. Brandt, Ofer Levy, John M. Esper, Andreas Kleen, Christopher M. Chrulski
  • Patent number: 10684191
    Abstract: Some demonstrative embodiments include apparatuses, systems and/or methods of determining one or more optical parameters of a lens of eyeglasses. For example, a product may include one or more tangible computer-readable non-transitory storage media including computer-executable instructions operable to, when executed by at least one computer processor, enable the at least one computer processor to implement operations of determining one or more optical parameters of a lens of eyeglasses. The operations may include processing at least one image of an object captured via the lens; and determining the one or more optical parameters of the lens based on the at least one image.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: June 16, 2020
    Assignee: 6 OVER 6 VISION LTD.
    Inventors: Ofer Limon, Haim Bachar, Nir Altmark, Shahar Levy
  • Patent number: 10670494
    Abstract: Some demonstrative embodiments include apparatuses, systems and/or methods of determining one or more optical parameters of a lens of eyeglasses. For example, a product may include one or more tangible computer-readable non-transitory storage media including computer-executable instructions operable to, when executed by at least one computer processor, enable the at least one computer processor to process at least one captured image of at least one reflection of a flash on a lens of eyeglasses; and determine one or more optical parameters of the lens based at least on the at least one captured image.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: June 2, 2020
    Assignee: 6 OVER 6 VISION LTD.
    Inventors: Ofer Limon, Shahar Levy, Alexander Zlotnik, Maya Aviv
  • Publication number: 20200108139
    Abstract: The methods and compositions described herein relate to methods of immunization or stimulating an immune response, e.g., using agonists of TLR7 and/or TLR8 as antigens. The methods and compositions described herein have particular relevance to use in infants.
    Type: Application
    Filed: March 23, 2018
    Publication date: April 9, 2020
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, UNIVERSITY OF MONTANA
    Inventors: Ofer LEVY, David DOWLING, Helene BAZIN-LEE, David BURKHART, Jay EVANS, Alyson Jessica SMITH
  • Patent number: 10592244
    Abstract: An example processor that includes a decoder, an execution circuit, a counter, and a last branch recorder (LBR) register. The decoder may decode a branch instruction for a program. The execution circuit may be coupled to the decoder, where the execution circuit may execute the branch instruction. The counter may be coupled to the execution circuit, where the counter may store a cycle count. The LBR register coupled to the execution circuit, where the LBR register may include a counter field to store a first value of the counter when the branch instruction is executed and a type field to store type information indicating a type of the branch instruction.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: March 17, 2020
    Assignee: Intel Corporation
    Inventors: Michael W. Chynoweth, Jonathan D. Combs, Joseph K. Olivas, Beeman C. Strong, Rajshree A. Chabukswar, Ahmad Yasin, Jason W. Brandt, Ofer Levy, John M. Esper, Andreas Kleen, Christopher M. Chrulski